Inflammatory disease of the bile ducts–cholangiopathies: liver biopsy challenge and clinicopathological correlation
Bernard Portmann
Institute of Liver Studies, King’s College Hospital, London, UK
Search for more papers by this authorYoh Zen
Institute of Liver Studies, King’s College Hospital, London, UK
Search for more papers by this authorBernard Portmann
Institute of Liver Studies, King’s College Hospital, London, UK
Search for more papers by this authorYoh Zen
Institute of Liver Studies, King’s College Hospital, London, UK
Search for more papers by this authorAbstract
Portmann B & Zen Y (2012) Histopathology 60, 236–248 Inflammatory disease of the bile ducts–cholangiopathies: liver biopsy challenge and clinicopathological correlation
Liver biopsy interpretation in inflammatory diseases of the bile ducts or chronic cholangiopathies may be challenging, especially for pathologists working outside referral centres, where there is a limited exposure to relatively uncommon conditions. In view of the importance of sampling errors resulting from the patchy distribution of pathognomonic bile duct injuries and the misleading absence of cholestasis in the early stages, there is a need to recognize surrogate markers and subtle changes, in particular the early periportal deposition of copper and mild biliary interface activity. Such findings may either constitute the first indication of a primarily biliary disorder or be supportive of a clinically suspected diagnosis. Histological changes common to chronic cholangiopathies are reviewed at the variable stages of development that patients may first present to clinicians. As awareness of the protean clinical manifestations is essential for histological interpretation, the major and distinctive anatomoclinical features of primary biliary cirrhosis and primary and acquired sclerosing cholangitis are revisited, together with so-called overlapping syndromes and less common variants and associations, including more recently documented conditions, such as IgG4-related disease and the rarer multidrug resistance 3 deficiency. The review stresses the importance of evaluating histological changes in conjunction with clinical information.
References
- 1 Portmann BC, Nakanuma Y. Diseases of the bile ducts. In AD Burt, BC Portmann, LD Ferrell eds. MacSween’s pathology of the liver, 5th edn. London: Elsevier, 2007; 517–581.
- 2 Guarascio P, Yentis F, Cevikbas U, Portmann B, Williams R. Value of copper-associated protein in diagnostic assessment of liver biopsy. J. Clin. Pathol. 1983; 36; 18–23.
- 3 Roskams TA, Theise ND, Balabaud C et al. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology 2004; 39; 1739–1745.
- 4 Harada K, Kono N, Tsuneyama K, Nakanuma Y. Cell-kinetic study of proliferating bile ductules in various hepatobiliary diseases. Liver 1998; 18; 1277–1284.
- 5 Portmann B, Popper H, Neuberger J, Williams R. Sequential and diagnostic features in primary biliary cirrhosis based on serial histologic study in 209 patients. Gastroenterology 1985; 88; 1777–1790.
- 6 Denk H, Lackinger E. Cytoskeleton in liver diseases. Semin. Liver Dis. 1986; 6; 199–211.
- 7 Ludwig J. Idiopathic adulthood ductopenia: an update. Mayo Clin. Proc. 1998; 73; 285–291.
- 8 Desmet VJ. Vanishing bile duct syndrome in drug-induced liver disease. J. Hepatol. 1997; 26(Suppl. 1); 31–35.
- 9 Murphy JR, Sjögren MH, Kikendall JW, Peura DA, Goodman Z. Small bile duct abnormalities in sarcoidosis. J. Clin. Gastroenterol. 1990; 12; 555–561.
- 10
Hübscher SG,
Lumley MA,
Elias E.
Vanishing bile duct syndrome: a possible mechanism for intrahepatic cholestasis in Hodgkin’s lymphoma.
Hepatology
1993; 7; 70–77.
10.1002/hep.1840170114 Google Scholar
- 11 Selmi C, Invernizzi P, Zuin M, Podda M, Gershwin ME. Genetics and geoepidemiology of primary biliary cirrhosis: following the footprints to disease etiology. Semin. Liver Dis. 2005; 25; 265–280.
- 12 Agmon-Levin N, Shapira Y, Selmi C et al. A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. J. Autoimmun. 2010; 34; 55–58.
- 13 Hohenester S, Oude-Elferink RP, Beuers U. Primary biliary cirrhosis. Semin. Immunopathol. 2009; 31; 283–307.
- 14 Hiramatsu K, Aoyama H, Zen Y, Aishima S, Kitagawa S, Nakanuma Y. Proposal of a new staging and grading system of the liver for primary biliary cirrhosis. Histopathology 2006; 49; 466–478.
- 15 Nakanuma Y, Zen Y, Harada K et al. Application of a new histologic staging and grading system for primary biliary cirrhosis to liver biopsy specimens: interobserver agreement. Pathol. Int. 2010; 60; 167–174.
- 16 Corpechot C, Carrat F, Bahr A, Chrétien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005; 128; 297–303.
- 17 Colina F, Pinedo F, Solis JA, Moreno D, Nevado M. Nodular regenerative hyperplasia of the liver in early histologic stages of primary biliary cirrhosis. Gastroenterology 1992; 102; 1319–1324.
- 18 Michieletti P, Wanless IR, Katz A et al. Antimitochondrial antibody negative primary biliary cirrhosis: a distinctive syndrome of autoimmune cholangitis. Gut 1994; 35; 260–265.
- 19 Mendes F, Lindor KD. Antimitochondrial antibody-negative primary biliary cirrhosis. Gastroenterol. Clin. North Am. 2008; 37; 479–484.
- 20 Beuers U, Rust C. Overlap syndromes. Semin. Liver Dis. 2005; 25; 311–320.
- 21 Chazouilleres O, Wendum D, Serfaty L, Rosmorduc O, Poupon R. Long term outcome and response to therapy of primary biliary cirrhosis–autoimmune hepatitis overlap syndrome. J. Hepatol. 2006; 44; 400–406.
- 22 Lohse AW, zum Büschenfelde KH, Franz B, Kanzler S, Gerken G, Dienes HP. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999; 29; 1078–1084.
- 23 O’Brien C, Joshi S, Feld JJ, Guindi M, Dienes HP, Heathcote EJ. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology 2008; 48; 550–556.
- 24 Björnsson E, Olsson R, Bergquist A et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 2008; 134; 975–980.
- 25 Weber C, Kuhlencordt R, Grotelueschen R et al. Magnetic resonance cholangiopancreatography in the diagnosis of primary sclerosing cholangitis. Endoscopy 2008; 40; 739–745.
- 26 Gregorio GV, Portmann B, Karani J et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001; 33; 543–544.
- 27 Boberg KM, Fausa O, Haaland T et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnostic of autoimmune hepatitis. Hepatology 1996; 23; 1369–1376.
- 28 Houry S, Languille O, Hugier M, Benhamou J-P, Belghiti J, Msika S. Sclerosing cholangitis induced by formaldehyde solution injected into the biliary tree of rats. Arch. Surg. 1990; 125; 1059–1061.
- 29 Gey T, Bergoin C, Just N et al. Langerhans cell histiocytosis and sclerosing cholangitis in adults. Rev. Mal. Respir. 2004; 21; 997–1000.
- 30 Zen Y, Harada K, Sasaki M et al. IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis: do they belong to a spectrum of sclerosing pancreatitis? Am. J. Surg. Pathol. 2004; 28; 1193–1203.
- 31 Björnsson E, Chari ST, Smyrk TC, Lindor K. Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology 2007; 45; 1547–1554.
- 32 Nakanuma Y, Zen Y. Pathology and immunopathology of immunoglobulin G4-related sclerosing cholangitis: the latest addition to the sclerosing cholangitis family. Hepatol. Res. 2007; 37(Suppl. 3); S478–S486.
- 33 Hamano H, Kawa S, Uehara T et al. Immunoglobulin G4-related lymphoplasmacytic sclerosing cholangitis that mimics infiltrating hilar cholangiocarcinoma: part of a spectrum of autoimmune pancreatitis? Gastrointest. Endosc. 2005; 62; 152–157.
- 34 Umemura T, Zen Y, Hamano H et al. Immunoglobin G4-hepatopathy: association of immunoglobin G4-bearing plasma cells in liver with autoimmune pancreatitis. Hepatology 2007; 46; 463–471.
- 35 Deshpande V, Sainani NI, Chung RT et al. IgG4-associated cholangitis: a comparative histological and immunophenotypic study with primary sclerosing cholangitis on liver biopsy material. Mod. Pathol. 2009; 22; 1287–1295.
- 36 Mendes FD, Jorgensen R, Keach J et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am. J. Gastroenterol. 2006; 101; 2070–2075.
- 37 Zhang L, Lewis JT, Abraham SC et al. IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis. Am. J. Surg. Pathol. 2010; 34; 88–94.
- 38 De Angelis C, Mangone M, Bianchi M et al. An update on AIDS-related cholangiopathy. Minerva Gastroenterol. Dietol. 2009; 55; 79–82.
- 39 Walther Z, Topazian MD. Isospora cholangiopathy: case study with histologic characterization and molecular confirmation. Hum. Pathol. 2009; 40; 1342–1346.
- 40 Rodrigues F, Davies EG, Harrison P et al. Liver disease in children with primary immunodeficiencies. J. Pediatr. 2004; 145; 333–339.
- 41 Hadzic N. Liver disease in primary immunodeficiencies. J. Hepatol. 2000; 32(Suppl. 2); 9–10.
- 42 Tomizawa D, Imai K, Ito S et al. Allogeneic hematopoietic stem cell transplantation for seven children with X-linked hyper-IgM syndrome: a single center experience. Am. J. Hematol. 2004; 76; 33–39.
- 43 Hadzic N, Pagliuca A, Rela M et al. Correction of hyper IgM after liver and bone marrow transplantation. N. Engl. J. Med. 2000; 342; 320–324.
- 44 Herrmann G, Lorenz M, Kirkowa-Reimann M, Hottenrott C, Hübner K. Morphological changes after intra-arterial chemotherapy of the liver. Hepatogastroenterology 1987; 34; 5–9.
- 45 Ludwig J, Kim CH, Wiesner RH, Krom RA. Floxuridine-induced sclerosing cholangitis: an ischemic cholangiopathy? Hepatology 1989; 9; 215–218.
- 46 Phongkitkarun S, Kobayashi S, Varavithya V, Huang X, Curley SA, Charnsangavej C. Bile duct complications of hepatic arterial infusion chemotherapy evaluated by helical CT. Clin. Radiol. 2005; 60; 700–709.
- 47 Heidenhain C, Pratschke J, Puhl G et al. Incidence of and risk factors for ischemic-type biliary lesions following orthotopic liver transplantation. Transpl. Int. 2010; 23; 14–22.
- 48 Cherqui D, Plazzo L, Piedbois P et al. Common bile duct stricture as a late complication of upper abdominal radiotherapy. J. Hepatol. 1994; 20; 693–697.
- 49 Kakar S, Batts KP, Poterucha JJ, Burgart LJ. Histologic changes mimicking biliary disease in liver biopsies with venous outflow impairment. Mod. Pathol. 2004; 17; 874–878.
- 50 Hernandez IG, Shandoval MW, Mendez EL, Calloros JH, Tapia AR, Uribe M. Biliary stricture caused by portal biliopathy: case report and literature review. Ann. Hepatol. 2005; 4; 286–288.
- 51 Jacquemin E, De Vree JM, Cresteil D et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001; 120; 1448–1458.
- 52 Lucena JF, Herrero JI, Quiroga J et al. A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis. Gastroenterology 2003; 124; 1037–1042.
- 53 Burak KW, Pearson DC, Swain MG, Kelly J, Urbanski SJ, Bridge RJ. Familial idiopathic adulthood ductopenia: a report of five cases in three generations. J. Hepatol. 2000; 32; 159–163.
- 54 Gotthardt D, Runz H, Keitel V et al. A mutation in the canalicular phospholipid transporter gene, ABCB4, is associated with cholestasis, ductopenia, and cirrhosis in adults. Hepatology 2008; 48; 1157–1166.